WO2013084070A3 - Salmonella vaccine proteins - Google Patents

Salmonella vaccine proteins Download PDF

Info

Publication number
WO2013084070A3
WO2013084070A3 PCT/IB2012/002944 IB2012002944W WO2013084070A3 WO 2013084070 A3 WO2013084070 A3 WO 2013084070A3 IB 2012002944 W IB2012002944 W IB 2012002944W WO 2013084070 A3 WO2013084070 A3 WO 2013084070A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
infection
salmonella spp
salmonella vaccine
vaccine proteins
Prior art date
Application number
PCT/IB2012/002944
Other languages
French (fr)
Other versions
WO2013084070A2 (en
Inventor
Brett B. Finlay
Brian Coombes
Rosana Ferreira
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of WO2013084070A2 publication Critical patent/WO2013084070A2/en
Publication of WO2013084070A3 publication Critical patent/WO2013084070A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods for the treatment or prevention of Gram negative bacterial, such as Salmonella spp. infection, in a vertebrate subject are provided. The methods provide administering a composition to the vertebrate subject in an amount effective to reduce or eliminate the Salmonella spp. bacterial infection and/or induce an immune response to the protein. Methods for the treatment or prevention of Salmonella spp. infection in a vertebrate are also provided. Other compositions and methods are also disclosed.
PCT/IB2012/002944 2011-12-06 2012-12-06 Salmonella vaccine proteins WO2013084070A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567526P 2011-12-06 2011-12-06
US61/567,526 2011-12-06

Publications (2)

Publication Number Publication Date
WO2013084070A2 WO2013084070A2 (en) 2013-06-13
WO2013084070A3 true WO2013084070A3 (en) 2013-08-08

Family

ID=48575011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/002944 WO2013084070A2 (en) 2011-12-06 2012-12-06 Salmonella vaccine proteins

Country Status (1)

Country Link
WO (1) WO2013084070A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103558388B (en) * 2013-10-24 2015-06-10 江南大学 Double-antibody sandwich method for detecting salmonella typhimurium in food based on monoclonal antibodies
CN104792991B (en) * 2015-04-17 2016-08-17 江南大学 The specific diabodies sandwich assay that a kind of detection Salmonella in Food based on monoclonal antibody belongs to
US11236135B2 (en) 2017-04-27 2022-02-01 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Salmonella and immunogenic composition containing the same as well as its use
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIL-CRUZ ET AL.: "The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response", PNAS, vol. 106, June 2009 (2009-06-01), pages 9803 - 9808, XP002564409 *
SIMON ET AL.: "Salmonella enterica serovar enteritidis core 0 polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis", INFECTION AND IMMUNITY, vol. 79, October 2011 (2011-10-01), pages 4240 - 4249, XP002675655 *

Also Published As

Publication number Publication date
WO2013084070A2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
WO2012092469A3 (en) Clostridium difficile antigens
SG10201804809RA (en) Clostridium difficile antibodies
WO2012097185A3 (en) Omv vaccine against burkholderia infections
WO2012145491A3 (en) Composition and method for enhancing an immune response
MX350325B (en) Bacterium for use as a probiotic for nutritional and medical applications.
WO2011152566A3 (en) Composition for inducing proliferation or accumulation of regulatory t cells
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
IN2012DN01898A (en)
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
MX366368B (en) Prebiotic oral care methods using a saccharide.
WO2012023051A3 (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
WO2013106689A8 (en) Hcv ns3 protease inhibitors
WO2012061248A8 (en) Novel specific hcv ns3 protease inhibitors
WO2013084070A3 (en) Salmonella vaccine proteins
WO2012151279A3 (en) Induction of il-12 using immunotherapy
WO2009115509A3 (en) Antigenic protein fragments of streptococcus pneumoniae
NZ700467A (en) Treatments suitable for malassezia infections
MX355719B (en) Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction and xanthan gum.
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
ZA201308256B (en) Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12856428

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12856428

Country of ref document: EP

Kind code of ref document: A2